Melanoma is the 6th most common cancer in Europe and has been increasing in incidence over the last 4 decades (1). While traditionally metastatic disease carried a poor prognosis, BRAF-targeted and immune checkpoint inhibition has improved median overall survival (OS) in metastatic patients. There is evidence that shows metastasectomy is associated with improved OS in patients that respond to targeted molecular or immunotherapy (2). While urogenital metastases are rare, with less than 30 cases of metastatic melanoma to the bladder in the literature (3), they are accessible for local and radical surgical resection. Imaging has a role in the identification of metastases and subsequent surgical planning.